VIM and cancer: SB-431542 treatment decreased dose-dependently vimentin expression in Colo320 and HT29NRP2 cancer cells and even restored E-Cadherin levels in HT29NRP2 underlying that TGFRI plays an essential role in the maintenance of the EMT phenotype conferred by NRP2 (Figure 6B).